Kevin Ho

Mr. Kevin Ho

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

11 May 2023 in Cells
Verified
Journal Article
Open access
PDF file
OMOliver Moore
Oliver Moore
KHKevin Ho
Kevin Ho
JCJuwan S. Copeland
Juwan S. Copeland
VPVaidya Parthasarathy
Vaidya Parthasarathy
Xander WehrensXander Wehrens
Xander Wehrens
This article reviews progress in the field of cardiac genome editing, in particular, its potential utility in treating cardiac arrhythmias. First, we discuss genome editing methods by which DNA can be disrupted, inserted, deleted, or corrected in cardiomyocytes. Second, we provide an overview of in vivo genome editing in preclinical models of heritable and acquired arrhythmias. Third, we discuss recent advancements in cardiac gene transfer, including delivery methods, gene expression optimization, and potential adverse effects associated with therapeutic somatic genome editing. While genome editing for cardiac arrhythmias is still in its infancy, this approach holds great promise, especially for inherited arrhythmia syndromes with a defined genetic defect.

1 November 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
KHKevin Ho
Kevin Ho
JKJoshua A. Keefe
Joshua A. Keefe
SZShuai Zhao
Shuai Zhao
MHMohit Hulsurkar
Mohit Hulsurkar
SJSung Yun Jung
Sung Yun Jung
Xander WehrensXander Wehrens
Xander Wehrens
Our study reveals a rare MRC2 gene variant (E990G) linked to familial supraventricular tachycardia and Wolff–Parkinson–White syndrome increases atrial fibrillation (AF) susceptibility in mice. The E990G-heterozygous variant disrupts atrial cardiofibroblast function, reducing protective matrix metalloproteinases (MMP-12 and MMP-13) and elevating profibrotic CCN2/CTGF levels, as shown through transcriptomic and proteomic profiling. This suggests that MRC2 deficiency promotes AF by altering fibrotic regulation in atrial tissue.

11 December 2024 in Journal of General Physiology
Verified
Journal Article
Open access
AHAmy D. Hanna
Amy D. Hanna
TCTing Chang
Ting Chang
KHKevin Ho
Kevin Ho
RYRachel Sue Zhen Yee
Rachel Sue Zhen Yee
WWWilliam Cameron Walker
William Cameron Walker
SHSusan L. Hamilton
Susan L. Hamilton
Dilated cardiomyopathy (DCM) is a highly prevalent and genetically heterogeneous condition that results in decreased contractility and impaired cardiac function. The FK506-binding protein FKBP12 has been implicated in regulating the ryanodine receptor in skeletal muscle, but its role in cardiac muscle remains unclear. To define the effect of FKBP12 in cardiac function, we generated conditional mouse models of FKBP12 deficiency. We used Cre recombinase driven by either the α-myosin heavy chain, (αMHC) or muscle creatine kinase (MCK) promoter, which are expressed at embryonic day 9 (E9) and E13, respectively. Both conditional models showed an almost total loss of FKBP12 in adult hearts compared with control animals. However, only the early embryonic deletion of FKBP12 (αMHC-Cre) resulted in an early-onset and progressive DCM, increased cardiac oxidative stress, altered expression of proteins associated with cardiac remodeling and disease, and sarcoplasmic reticulum Ca2+ leak. Our findings indicate that FKBP12 deficiency during early development results in cardiac remodeling and altered expression of DCM-associated proteins that lead to progressive DCM in adult hearts, thus suggesting a major role for FKBP12 in embryonic cardiac muscle.